Pharmacology and Toxicology Seminar Series:
Hydrogen Sulfide in Cardiovascular Disease
David J. Lefer, Ph.D.
Emory University School of Medicine, Department of Surgery-Division of Cardiothoracic Surgery, Carlyle Fraser Heart Center, Atlanta, GA
Recent experimental evidence has revealed that the body produces a third gaseous signaling molecule (H2S) in addition to nitric oxide (NO) and carbon monoxide (CO). In fact, there have now been 3 H2S-generating enzymes identified (CSE, CBS, and 3-MST) in mammals that produce H2S throughout the body. H2S has emerged as an exciting pharmacological target for the treatment of a number of cardiovascular disease states given it's diverse physiological.Our laboratory has focused on the investigation of the cardioprotective actions of H2S in preclinical models of acute myocardial infarction and heart failure. Data will be presented for the effects of genetic gain and loss of function of H2S generating enzymes using highly novel transgenic mouse models. In addition, data will also be presented describing the use of novel therapeutic agents that augment circulating and tissue levels of H2S during both acute and chronic cardiovascular disease states.